Form 4: AnaptysBio Director Sells Shares to Cover Tax Obligations Under Pre-Arranged Plan

AnaptysBio Director Hollings Renton sold 3,015 shares of common stock at $23.97 per share on June 18, 2025, to satisfy tax obligations related to the vesting of restricted stock units.

Summary

• Hollings Renton, a Director at AnaptysBio, Inc. (ANAB), reported a sale of common stock.
• The transaction involved the disposition of 3,015 shares of AnaptysBio common stock.
• The shares were sold at a price of $23.97 per share.
• The sale occurred on June 18, 2025.
• Following this transaction, Hollings Renton beneficially owns 4,965 shares of AnaptysBio common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the Reporting Person on March 14, 2024.
• The purpose of the sale was to satisfy a portion of the tax obligation incurred in connection with the vesting of restricted stock units (RSUs) on June 15, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine, pre-planned sale for tax purposes related to RSU vesting, which is a common occurrence and not indicative of a change in the director's confidence in the company's prospects.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and routine transaction rather than a discretionary sale based on new information.
• The sale was specifically for tax withholding purposes related to RSU vesting, which is a common and expected event for executives and directors receiving equity compensation.

Negatives

• A director selling shares, even for tax purposes, reduces their direct ownership stake in the company.

Risks

• While the sale was for tax purposes, any insider selling, regardless of the reason, can sometimes be misinterpreted by the market as a lack of confidence, potentially leading to short-term negative sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook. It solely reports a past insider transaction.

Management Comments

• The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024.
• Shares were sold to satisfy a portion of the tax obligation in connection with the vesting of restricted stock units on June 15, 2025.

Industry Context

Insider transactions, particularly those related to tax withholding from equity compensation, are common occurrences across all industries for publicly traded companies. The use of a Rule 10b5-1 plan is a standard practice to allow insiders to sell shares in a pre-scheduled manner, mitigating concerns about trading on material non-public information.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for insider sales is a widely accepted corporate governance practice, aligning with industry standards for managing insider transactions transparently and compliantly.
• Sales to cover tax obligations upon RSU vesting are a routine and expected event for executives and directors across the biotech and pharmaceutical industries, similar to practices at companies like Amgen, Gilead Sciences, or Biogen, where equity compensation is a significant part of executive pay.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in a director's direct ownership, but given it's for tax purposes under a 10b5-1 plan, the impact on shareholder confidence is likely minimal.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• No specific future actions or milestones for the company are mentioned in this Form 4 filing, as it pertains solely to a past insider transaction.

Key Dates

Keywords

ANAPTYSBIO, ANAB, Form 4, insider trading, stock sale, director, restricted stock units, RSU vesting, 10b5-1 plan, equity compensation, tax obligation